A multicenter phase II study evaluating the efficacy and tolerability of vemurafenib in combination with Pegylated Interferon and Interleukin-2 in patients with BRAF-mutated metastatic melanoma

Trial Profile

A multicenter phase II study evaluating the efficacy and tolerability of vemurafenib in combination with Pegylated Interferon and Interleukin-2 in patients with BRAF-mutated metastatic melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2015

At a glance

  • Drugs Vemurafenib (Primary) ; Aldesleukin; Peginterferon alfa-2b
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Apr 2015 Status changed from recruiting to discontinued, as reported by European Clinical Trials Database record.
    • 14 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top